Life Science Investing Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Life Science Investing Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress
Life Science Investing Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Life Science Investing Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Pinnacle Receives Positive Results from Preliminary Metallurgical Tests at El Potrero with Average of 95.09% Gold Recovery
CHARBONE Announces the Official Start of Civil Construction Work in Sorel-Tracy, in Line with the Announced Schedule
CHARBONE annonce le debut officiel des travaux de construction civil a Sorel-Tracy, conformement a l'echeancier annonce
1911 Gold Strengthens Operations Leadership with Appointment of Éric Vinet as COO and Additional Senior Site Personnel
Acquisition of Option to Buy Lepidico's Interest in Karibib Lithium, Rubidium and Cesium Project in Namibia - Update
